NACCHO Highlights Results of New CDC Data on Gonorrhea Treatment Effectiveness

Appropriate Treatment Especially Critical in Light of Recent Drug-Resistant Gonorrhea Cases Says the National Association of County and City Health Officials

WASHINGTON, DISTRICT OF COLUMBIA, UNITED STATES, April 26, 2018 /EINPresswire.com/ — Today, the Centers for Disease Control and Prevention (CDC) released a new analysis in their Morbidity and Mortality Weekly Report (MMRW), “Adherence to CDC Recommendations for the Treatment of Uncomplicated Gonorrhea, STD Surveillance Network (SSuN), 2016.”

The new data shows that 81 percent of all patients diagnosed with gonorrhea were treated with the CDC-recommended dual therapy of ceftriaxone and azithromycin. This dual therapy has been the recommended treatment in recent years to attempt to slow the emergence and spread of drug resistance in gonorrhea. In particular, the National Association of County and City Health Officials (NACCHO), representing the nation’s nearly 3,000 local health departments, is encouraged by the data showing that patients visiting STD and reproductive health clinics are the most likely to receive the CDC-recommended dual therapy (91 and 94 percent respectively), compared with other healthcare settings, which provided the recommended dual therapy only 80 percent of the time. “These findings underscore that publicly funded STD and reproductive health clinics provide quality STD care,” said NACCHO Interim Executive Director and Chief of Government Affairs Laura Hanen, MPP. “However, we need all healthcare settings performing at this level in order to effectively treat gonorrhea, prevent new infections, and slow the threat of drug resistant gonorrhea.”

Continued Hanen, “This data shows how essential the work of health departments is in the effort to treat STDs, especially in light of potential drug resistant gonorrhea. This requires that local health departments monitor adherence to CDC’s recommendations, educate providers on the treatment of gonorrhea in accordance with those guidelines, and continue to work with providers and patients to assure timely detection and treatment of gonorrhea. The CDC must have adequate funding to ensure local and state health departments are equipped to undertake these efforts, while still serving other aspects of their community’s health. An infusion of resources at the local level is essential to the efforts to respond to the nationwide increases in STDs.”

The data on which this analysis was made was from the CDC’s SSuN (Sexually Transmitted Disease Surveillance Network), an innovative information network that delivers enhanced, updated data on STDs. This data allows for the access and use of quickly delivered, updated, and specific STD data to be monitored and tracked by health departments. SSuN data provides a fuller picture than traditional surveillance data, thereby allowing for quicker responses and improved allocation of scarce resources. This in turn allows for more effective treatment methods—such as the adoption of the dual therapy regimen in the treatment of gonorrhea.

One example of a local health department benefitting from SSuN data is Oregon’s Multnomah County Health Department. “The SSuN data has allowed our health department to measure differences in gonorrhea rates in specific racial and geographic communities, so that we can focus our resources to make the biggest difference for clients,'' said Rachael Banks, Multnomah County Public Health Director.

###

About NACCHO
The National Association of County and City Health Officials (NACCHO) represents the nation's nearly 3,000 local health departments. These city, county, metropolitan, district, and tribal departments work every day to protect and promote health and well-being for all people in their communities. For more information about NACCHO, please visit www.naccho.org.

Theresa Spinner
National Association of County and City Health Officials
202-783-5551
email us here


Source: EIN Presswire

Active Sexual Lifestyle? New ​Digital Health App Pairs with Social Sharing to Reduce the Spread of STDs

CheckMate Healthcare App Offers More Options for Preventative STD Testing. Demand for Tele-medicine and Digital Health Options Steadily Grows.

“We want everyone saying “Do you use CheckMate?” and “I just sent you my CheckMate results. It’s easier to talk about an
app than it is to talk about STDs””

— Marc Schonberger

BOCA RATON, FL, USA, April 26, 2018 /EINPresswire.com/ — Are medical apps the new tool to changing the future of healthcare? CheckMate Healthcare thinks so. The launch of CheckMate Healthcare’s new app is one of the latest tools for people to take control of preventative care. Available for iOS and Android, the app offers CheckMate Home and CheckMate Lab to deliver STD testing right to your door. Emerging as an easy and affordable e-Health testing alternative.

​With 48% of millennials using condoms “never” or “rarely” and STDs accounting for $16 billion in healthcare costs, CheckMate provides treatment and confidential results sharing options for better sexual health in a growing mobile lifestyle.

CheckMate is empowering people and making the STD conversation easier. “We want everyone saying “Do you use CheckMate?” and “I just sent you my CheckMate results.” says CheckMate founder Marc Schonberger. “It’s easier to talk about an
app than it is to talk about STDs” continues Schonberger.

This moves the conversation from the focus on treatment to the focus on prevention.​ Sexual health can be complicated but getting tested doesn’t have to be. Download the app, pick your test, ($70 to $229) return your kit and get accurate
results typically in 48 hours. ​Test results negative? Share your “Gold Pass” and let your partner know you’re STD free, with a text, email, link in your dating profile. Need a prescription? CheckMate provides free tele-medicine consults and support for positive STD results. Unlike any competitor, CheckMate is the market’s first
shareable STD app, ​and will be indispensable for life in the world of modern dating.

Users are encouraged to share the app and get $20 off the Total Check with code LAUNCH on CheckMate’s site. The growing MedTech phenomenon is more than a trend, and with high insurance deductibles, self-directed testing is prime to grow.
With a 20 year high in the rise of STDs, CheckMate is needed now more than ever. CheckMate has partnered with 2400 labs across the nation making your healthcare a priority. ​Easy, convenient, cost effective, and safe, MedTech is on the
rise and CheckMate is here to stay.

CheckMate’s founder, marketing director and healthcare experts, are all available for interviews in our booking calendar. ​We are scheduling now, and can provide more information as needed. You can find CheckMate's full press kit, trending ads, bios, and booking calendar available online here. Just click.

# # #

About CheckMate Healthcare

CheckMate Healthcare has introduced CheckMate, the World’s first STD testing, treatment and
confidential results sharing app. Checkmate provides pre-paid testing at thousands of lab
locations for quick and easy testing or our at home self-check kits for even more confidentiality
and ease. We provide revenue opportunities for strategic partners and app ambassadors.
Headquartered in Boca Raton, Florida, Checkmate was launched to address the STD epidemic
with a comprehensive and cost effective personal mobile healthcare and social media results
sharing solution. For more information, please visit www.checkmatehealthcare.com

Liz Galloway
Bosscat Productions
8018672452
email us here


Source: EIN Presswire

CheckMate Sharable STD App Brings Online "Dick Pic" Sharing Trend Into Mainstream to Help Teach Need For STD Testing

CheckMate Healthcare Pitches Top VC’s at HLTH Expo Vegas 2018 With New App Features to Help the Health of Millions of Americans

We want people to start saying do you use CheckMate? The same as when people say, “Let’s take an Uber”. We want to make the conversation between people easier regarding their sexual health”

— Chelsea Siefers

BOCA RATON, FL, USA, April 26, 2018 /EINPresswire.com/ — Boca Raton, FL April 22nd, 2018 — With STD’s at an all time high, and the trend of sexting, the rise of STD’s creates a true public health threat. CheckMate Healthcare’s digital health app provides a mobile option to drive more STD testing. CheckMate not only makes safe sex easier, it creates a cultural shift to start the sexual health conversation. Just like the trend of "dick pics” the trend in using e-health apps for healthcare is growing. CheckMate is at the forefront of this trend and has been chosen to pitch to top VCs May 6-9, at HLTH Expo 2018 on the app’s features and the conversation of disruptive information in healthcare. CheckMate is taking appointments for on site visits now.

”We want people to start saying do you use CheckMate? The same as when people say, “Let’s take an Uber”. We want to make the conversation between people easier regarding their sexual health” says CheckMate’s Director of New Business, Chelsea Seifers.

CheckMate’s fast, easy, convenient and sharable STD test result app is already being downloaded as a go for digitally driven health initiatives.

Ready to meet the perfect mate? Swiping right? Then it’s time to use the new mobile STD app from CheckMate, free in the iPhone and Google App Stores. CheckMate offers the ideal partnership between a social and medical app. CheckMate is the market’s top shareable app with at home self check kits and pre-paid testing at thousands of lab locations. It provides comprehensive tests for all genders, including PrEP testing (pre-exposure prophylaxis for high risk HIV exposure) from the privacy of your home.

Want to share your STD- free status? CheckMate developed its Gold Pass to make it easy, confidential and convenient to share your latest STD test results with your mate or potential new mates. Just forward your “Gold Pass” clean bill of health with your name, nickname, or anonymously. After viewing the results are gone, just like snapchat.

CheckMate’s founder, marketing director and healthcare experts, are available for interviews in our booking calendar, and will be available for appointments in person at HLTH Expo in Vegas. We are scheduling now, and can provide more information as needed. You can find your CheckMate full press kit, trending ads, bios, and booking calendar are available online here. Just click.

# # #

About CheckMate Healthcare

CheckMate Healthcare has introduced CheckMate, the World’s first STD testing, treatment and confidential results sharing app. Checkmate provides pre-paid testing at thousands of lab locations for quick and easy testing or our at home self-check kits for even more confidentiality and ease. We provide revenue opportunities for strategic partners and app ambassadors. Headquartered in Boca Raton, Florida, Checkmate was launched to address the STD epidemic with a comprehensive and cost effective personal mobile healthcare and social media results sharing solution. For more information, please visit www.checkmatehealthcare.com

Liz Galloway
Bosscat Productions
8018672452
email us here


Source: EIN Presswire

The Pacific Mesothelioma Center is Excited to Announce the Start of Its Patient Support Group!

Mesothelioma Expert Lien Hua-Feng

LOS ANGELES, CA, U.S.A, April 26, 2018 /EINPresswire.com/ — The Pacific Mesothelioma Center (PMC) at the Pacific Heart, Lung & Blood Institute (PHLBI) is happy to announce the start of its new support group for mesothelioma patients. Nearly two years after the inception of its successful caregiver's group, the patient support group was created as a response to the growing number of individuals who expressed interest in a group centered on patients. The first meeting will be Wednesday, May 9th at 7 PM PST. The meeting will be held as a conference call every second Wednesday of the month through Uber Conference and will be moderated by PMC Nurse Practitioner and mesothelioma expert Lien Hua-Feng.

The support group will allow mesothelioma patients to discuss treatment experience with other patients, how to overcome side effects, share stories, and to ask questions about this rare cancer. Mesothelioma is an aggressive cancer caused by exposure to asbestos with few treatment options. It affects approximately 3,000 individuals in the United States each year, one-third of whom are veterans who were exposed to asbestos during military service. The rarity of this cancer limits the scope of the public’s awareness and funding for research into better treatment options.

The mission of the PMC is to generate hope through research, support, and education. The Pacific Mesothelioma Center is engaged in groundbreaking research to develop next-generation immunotherapies. PMC researchers have discovered an innovative approach to convert human mesenchymal stem cells (MSCs) into potent immune-boosting treatments that will pave the way for an entirely new class of immunotherapies that could be effective against a wide variety of cancer types, including the most aggressive ones like mesothelioma.

If you are a mesothelioma patient interested in participating on the call, please contact Christina McSherry at (310)-478-4678 or by email at christinam@phlbi.org.

Christina McSherry
The Pacific Mesothelioma Center
(310)-478-4678
email us here


Source: EIN Presswire

Growing Emerging Economy Demand For Livestock Products Will Boost Veterinary Services Market

Global Veterinary Market Segments 2017

Global Veterinary Market Segments 2017

LONDON, GREATER LONDON, UK, April 26, 2018 /EINPresswire.com/ — The global livestock and poultry population is expected to rise in the years to 2021, a report from The Business Research Company shows. According to the USDA, in 2016, the USA’s commercial production of beef is expected to increase by almost 4% while beef and boiler meat exports are forecast to grow by 9% and 7%, respectively. This trend is especially prominent in developing countries such as China, India and Brazil. China is a world leader in pork production and its meat production increased from less than 70 million tons in 2010 to more than 76 million tons in 2016. Increasing population and rising income levels are stimulating the demand for livestock products in emerging markets. The global veterinary services market is benefiting. A threat remains, however: the large US pigs and pork export market to China may be affected by tit-for-tat tariffs or quotas imposed by the Chinese government in retaliation for US trade restrictions on steel and aluminum.

More Stringent Livestock Regulations

Regulations surrounding the maintenance of cattle and livestock are increasing the demand for veterinary services. For instance, in March 2016 the United States Food and Drug Administration (FDA) announced an amendment in its humanly medically important antibiotics regulations. With effect from 2017, cattle owners need to administer the Veterinary Feed Directive (VFD) drugs under the supervision of licensed veterinarians. Thus, increasingly stringent rules and regulations surrounding the production and export of cattle and meat products are expected to drive the veterinary services market up to 2021.

Market Segments

One major split in the veterinary services market is between treatment centres such as animal hospitals, clinics and surgeries and veterinary laboratories. Pet foods and products such as pharmaceuticals sold through animal hospitals are a third category.

Although the treatment centres provide some diagnostic services, their main functions are dispensary, surgery, radiology, clinical pathology, ward accommodation and facilities for 24-hour observation of patients and outreach work, especially on farms. Specialized treatments such as advanced diagnostic services, internal medicine, oncology, neurology, endocrinology, ophthalmology, dermatology and cardiology are widely available in the bigger animal hospitals. Globally a little under 40% of the work of the animal hospitals and clinics is routine examinations, another nearly 40% is non-surgical procedures and the remaining 20% or so is surgical procedures.

Laboratory services perform laboratory tests as prescribed by the veterinary practitioner for the diagnosis and treatment of animal diseases by testing for infectious agents and toxins in animal diagnostic samples. The operations of a veterinary testing laboratory include the study of the composition, structure, properties and chemical and biological processes occurring in the objects of veterinary medicine. Tests in the veterinary testing laboratories include chemistry, pathology, endocrinology, serology, hematology and microbiology.

The pet food and product sales segment comprises the sale of pet food and related products channeled through veterinary clinics and hospitals. These pet food and related products are generally provided as a part of the veterinary service to animals being treated. Prescription diets are formulated to meet the specific nutritional needs for certain illnesses and conditions. Conditions that benefit from prescription diets include diabetes, kidney disease, liver disease, obesity, arthritis, allergies, pancreatitis, and many more. Nutritional supplements will also be recommended based on a pet’s individual metabolism and state of health. The food for livestock or for pets bought at retail is not included in this category, because it is not generally supplied through veterinary clinics and the supply chain is different.

Where To Learn More
Read the Veterinary Services Global Market Report 2018 from The Business Research Company for information on the following:
Markets Covered: Veterinary services, healthcare.
Veterinary Service Companies Covered: VCA Inc., Banfield Pet Hospital, Greencross Ltd., CVS Group Plc, The Bargh Memorial Animal Hospital ASPCA, The Animal Medical Center.CA Inc.
Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.
Countries: USA, China, UK, Japan, France, Germany, Australia, India, Spain, Russia, Italy, Brazil
Time Series: Five years historic (2013-17) and forecast (2017-21).
Data Segmentations: Veterinary services market historic and forecast size and growth rates for the world, 7 regions and 12 countries, animal hospitals and clinics, laboratory services and pet food and product segments historic and forecast size and growth rates for the world, 7 regions and 12 countries, animal hospital and clinic routine examinations, surgical procedures and non-surgical procedures for 12 countries, livestock and pets segments size 2017 for 12 countries, global competitor sales and market shares.
Healthcare market historic and forecast size and growth rates for the world, 7 regions and 12 countries, healthcare market size, percentage of gdp, global, healthcare per capita expenditure, by country, healthcare services market historic and forecast size and growth rates, and split by segments 2017, global.
Other Data: Veterinary services expenditure as % of GDP, per capita veterinary services expenditure, pet population split by type, by country, 2017, livestock and poultry population by country, 2017, global veterinary services and healthcare market growth rate comparison.
Other Information: Drivers and restraints of the global veterinary services market 2013-17 and 2017-21, Porter’s Five Forces Model, PESTEL analysis and customer information for the global veterinary services market, company profiles including products, strategy and financial performance for 6 veterinary service companies, veterinary services market trends and Strategies
Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.

Interested to know more? Here is a list of reports similar to “Veterinary Services Global Market Report 2018”:
1. Veterinary Healthcare Global Market Report 2018 (https://www.thebusinessresearchcompany.com/report-preview.aspx?id=335)
2. Animal Medicine Global Market Report 2018 (https://www.thebusinessresearchcompany.com/report-preview.aspx?id=388)
3. Veterinary Medical Equipment Global Market Report 2018 (https://www.thebusinessresearchcompany.com/report-preview.aspx?id=387)

Oliver Guirdham
The Business Research Company
+44 207 1930 708
email us here


Source: EIN Presswire

Speaker Interview with Pau Aceves Released – SMi’s 13th Annual ADMET conference

ADMET Event

ADMET conference an in-depth exploration of the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals.

LONDON, GREATER LONDON, UNITED KINGDOM, April 26, 2018 /EINPresswire.com/ — The event will be taking place at the Holiday Inn Kensington Forum in London, UK on the 9th and 10th July 2018.

An interview with Pau Aceves, Associate Director, Certara Strategic Consulting, has just been released and is available for download on the event website. Mr Aceves will be presenting ‘Applications of PKPD modelling in oncology – an overview’ where he will be discussing binary safety/efficacy endpoints, how patients’ individual characteristics may have as big of an impact as e.g. safety response as solely a dose, how to best manage toxicity, and PK and PKPD time-course describe via a mechanistic model.

Snapshot of Interview with Pau Aceves:

Where do you see the greatest opportunities for ADME-T leaders?

• ‘I see the advent of Machine Learning and Artificial Intelligence as a great opportunity for ADME-T leaders to automatize and increase the productivity and solve nowadays data challenges in R&D. We are nearing a point where human effort alone will no longer be able to process the quantity of data that is being generated. Hence, I believe that the Companies that are able to harness these technologies will become the leaders of drug development in decades to come.’

What are the main challenges in your day-to-day work relating to drug discovery?

• ‘I work mainly in clinical development, so one of my main challenges is the coordination with other drug discovery scientists to ensure that the required data for modelling and simulation are generated during early stages to enable translational PK/PD modelling (i.e. Pop PK/PD, PBPK and QSP).’

This year’s two-day conference will also feature over 15 expert-level speakers from organisations such as AbbVie, Roche, Bayer, GlaxoSmithKline and many more, discussing new technologies, specific case studies and PK modelling strategies in the areas of DMPK, PBPK, PKPD, in vitro / ex vivo / in vivo / in silico, biologics, transporters, hazard and safety assessments, ADMET modelling, and much more.

To download the full interview, as well as the 2018 agenda and speaker line-up, visit the website at:
www.admet-event.com/PR1

________________________________________
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
________________________________________

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

ADMET
9th – 10th July 2018
Holiday Inn Kensington Forum, London, UK
www.admet-event.com/PR2

Contact e-mail: ssapal@smi-online.co.uk
Contact tel: +44 (0) 207 827 6000

Follow us @SMiPharm
#SMiADMET

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
02078276000
email us here


Source: EIN Presswire

Invite from the Chairman Hugues Malonne at SMI’s 5th Annual Molecular Diagnostics Conference

SMi proudly presents chairman Hugues Malonne, Director General, DG POST authorisation, Federal Agency for Medicines and Health Products.

LONDON, GREATER LONDON , UNITED KINGDOM, April 26, 2018 /EINPresswire.com/ — The 5th annual Molecular Diagnostics conference, will focus on evaluating the future of diagnostics for rapid detection and improved clinical outcomes.

The event will take place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshop on 11th July 2018.

Mr Malonne, who is co-chairing the two-day conference with David Crosby, Cancer Research, UK, has stated ‘As the co-chair for the event, I am particularly interested in you joining us to discuss the role of molecular diagnosis in the devolvement of personalised medicine, analyse the latest developments in companion diagnostics and discuss the future of the industry, learn what will be required in the new European In Vitro Diagnostics Regulations, assess opportunities and novel diagnostics technologies at the point-of-care, plus much more’.

On day one of the conference, Mr Malonne will be giving a presentation on ‘A National Competent Authority’s perspective on IVDR implementation’, where he will be discussing how the transition to IVDR can be supported and how to address the upcoming challenges associated.

The two-day event will feature over 16 presentations from highly-regarded, expert speakers hailing from big pharma companies, charities and medical institutions such as AstraZeneca, Cancer Research UK, Genentech and many more. The presentations will explore various topics on compliance with regulations across the globe, developing diagnostics, opportunities in point of care testing advancements in personalised medicine and much more.

Book by the 30th April to receive a £200 discount.

For the full agenda and speaker line-up, visit the website to download the brochure at www.molecular-diagnostics-conference.com/PR2
________________________________________
Interested in sponsoring, exhibiting or speaking at this event?
Contact Alia Malick, Director, on +44 (0) 20 827 6168 or email amalick@smi-online.co.uk
________________________________________

For media enquiries, contact Simi Sapal, Marketing on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk
Molecular Diagnostics
9th – 10th July 2018
Holiday Inn Kensington Forum, London, UK
www.molecular-diagnostics-conference.com/PR

Contact e-mail: ssapal@smi-online.co.uk
Contact tel: +44 (0) 207 827 6000
Follow us @SMiPharm
#SMiMolecularDx

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Simi Sapal
SMi Group
2078276000
email us here


Source: EIN Presswire

Mucomel® Phase II Results Selected to be Presented at ASCO

Spherium Biomed announced today the completion of its Phase I/IIa clinical trial of Mucomel®, for the prevention and treatment of oral mucositis.

BARCELONA, SPAIN, April 26, 2018 /EINPresswire.com/ — NEWS HIGHLIGHTS
Spherium Biomed announced today the completion of its Phase I/IIa clinical trial of Mucomel®, for the prevention and treatment of oral mucositis in head and neck cancer patients undergoing chemo-radiotherapy.

The trial was designed to include 84 patients with advanced disease receiving high dose radiotherapy and concomitant treatment with cisplatin or cetuximab enrolled from 11 hospitals in Spain.

The results will be presented by the leading investigator, Dr. Alicia Lozano, at the Head and Neck cancer oral abstract session of the ASCO meeting in Chicago on June 3rd.

MORE
Spherium Biomed has completed the analysis of the results of the Mucomel® trial, a phase I/IIb prospective, double blinded and placebo controlled trial to evaluate the safety and efficacy of its high dose melatonin gel, Mucomel®, for the prevention and treatment of oral mucositis (OM) in head and neck cancer patients receiving chemo-radiotherapy (NCT02630004).

The trial aimed to include 84 patients from 11 sites in Spain. The patients were selected among those scheduled to receive high dose radiation (at least 66 Gy) and concomitant cisplatin or cetuximab treatment for 2 months according to standard clinical practices for advanced grade head and neck cancer in Spain. Patients were instructed to use Mucomel® or placebo gels 5 times a day over the full course of the treatment.

The trial’s objectives were to evaluate safety and explore efficacy. The results will be fully disclosed at the oral abstract presentation of the Head & Neck Cancer track of the American Society of Clinical Oncology meeting in Chicago on June 3th according to the final program made public yesterday by the ASCO organizers (Abstract 6007, https://iplanner.asco.org/am2018/#/)

Mucositis is defined as inflammatory and/or ulcerative lesions of the gastrointestinal tract mucosa. Oral mucositis affects the oral mucosa causing erythematous and ulcerative lesions. It is particularly relevant in patients with cancer being treated with chemo- and/or radiation therapy, especially in high dose CT / RT in head and neck cancer patients. Severe oral mucositis leads to pain, changes in diet (including parenteral feeding), hospitalization and de-escalation of oncologic treatment.

There are more than 550.000 cases of Head and Neck cancer every year, and no drug is approved for the treatment or prevention of oral mucositis. The standard of care is based in pain medication and oral rinses or barrier devices to maintain mucosal integrity. Nearly 100% of patients receiving chemo and/or radio therapy will develop OM. 70% to 85% of patients receiving chemo-radio therapy will develop severe OM (Grades 3 or 4). At grade 3, the patients are in excruciating pain and cannot swallow solids; at Grade 4 the patients cannot drink and require feeding-tubes. In addition to head and neck cancer patients, 75% of patients receiving bone marrow transplantation for hematological cancer are expected to develop OM. In other types of cancer, 20-40% of patients receiving standard chemotherapy may also develop OM.

Mucomel® is based on a proprietary, patented high-load gel formulation of melatonin presented in individual 10ml sachets, to facilitate administration on out-patient basis. Spherium aims to partner the program during 2018 to complete development and reach patients worldwide as fast as possible.

ABOUT SPHERIUM (www.spheriumbiomed.com)

Spherium Biomed is a clinical-stage, biopharmaceutical portfolio company that sources its pipeline from academic research. The company applies a lean, hands-on venture builder model to advance its portfolio up to a relevant value milestone to increase the chance of academic discoveries reaching the market. The company applies its broad experience in drug development (from discovery to clinical and commercial stages) to deeply analyze the commercial potential of technologies. After defining the relevant gaps with respect to an ideal target product profile, the company acquires development and commercialization rights for the asset and derives a creative and cost-effective work plan to bring the project forward, and implements the plan with its own resources and the proactive coordination of external providers.

Spherium is privately owned; its major shareholders are its founders and key executives, and the Spanish pharmaceutical company Ferrer (www.ferrer.com). Its current portfolio includes three Phase II clinical stage projects and one Phase I. The portfolio includes several first-in-class preclinical projects as well, two of them undergoing IND-enabling regulatory safety-toxicology and industrial scaling up. The company is constantly looking for new opportunities addressing unmet clinical needs.

For more information please contact info@spheriumbiomed.com

Dr. Bill Mason
The Sage Group
+44 7785 950134
email us here


Source: EIN Presswire

Marine Algae Products Market 2018 Global Industry – Key Players Analysis, Sales, Supply, Demand and Forecast to 2025

Wiseguyreports.Com Publish New Market Report On -“Marine Algae Products Market – Global Industry Analysis, Size, Share, Trends, Growth and Forecast 2018 – 2025”

PUNE, INDIA, April 26, 2018 /EINPresswire.com/ —

Marine Algae Products Market 2018

This report studies the global Marine Algae Products market status and forecast, categorizes the global Marine Algae Products market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa).

The major manufacturers covered in this report
BASF
Cyanotech Corporation
Cargill
Dowdupont
Kerry
Ingredion
CP Kelco
Corbion
Roquette Freres
Fenchem Biotek
Algatechnologies
E.I.D. Parry

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3141769-global-marine-algae-products-market-research-report-2018

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
North America
Europe
China
Japan
Other Regions

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Lipids
Carrageenan
Carotenoids
Algal protein
Alginate
Others

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Food & Beverages
Nutraceuticals & Dietary Supplements
Feed
Personal Care Products
Pharmaceuticals
Others

Complete Report Details @ https://www.wiseguyreports.com/reports/3141769-global-marine-algae-products-market-research-report-2018

Table of Contents –Analysis of Key Points

Global Marine Algae Products Market Research Report 2018
1 Marine Algae Products Market Overview
1.1 Product Overview and Scope of Marine Algae Products
1.2 Marine Algae Products Segment by Type (Product Category)
1.2.1 Global Marine Algae Products Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
1.2.2 Global Marine Algae Products Production Market Share by Type (Product Category) in 2017
1.2.3 Lipids
1.2.4 Carrageenan
1.2.5 Carotenoids
1.2.6 Algal protein
1.2.7 Alginate
1.2.8 Others
1.3 Global Marine Algae Products Segment by Application
1.3.1 Marine Algae Products Consumption (Sales) Comparison by Application (2013-2025)
1.3.2 Food & Beverages
1.3.3 Nutraceuticals & Dietary Supplements
1.3.4 Feed
1.3.5 Personal Care Products
1.3.6 Pharmaceuticals
1.3.7 Others
1.4 Global Marine Algae Products Market by Region (2013-2025)
1.4.1 Global Marine Algae Products Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
1.4.2 North America Status and Prospect (2013-2025)
1.4.3 Europe Status and Prospect (2013-2025)
1.4.4 China Status and Prospect (2013-2025)
1.4.5 Japan Status and Prospect (2013-2025)
1.5 Global Market Size (Value) of Marine Algae Products (2013-2025)
1.5.1 Global Marine Algae Products Revenue Status and Outlook (2013-2025)
1.5.2 Global Marine Algae Products Capacity, Production Status and Outlook (2013-2025)
……..

7 Global Marine Algae Products Manufacturers Profiles/Analysis
7.1 BASF
7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.1.2 Marine Algae Products Product Category, Application and Specification
7.1.2.1 Product A
7.1.2.2 Product B
7.1.3 BASF Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.1.4 Main Business/Business Overview
7.2 Cyanotech Corporation
7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.2.2 Marine Algae Products Product Category, Application and Specification
7.2.2.1 Product A
7.2.2.2 Product B
7.2.3 Cyanotech Corporation Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.2.4 Main Business/Business Overview
7.3 Cargill
7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.3.2 Marine Algae Products Product Category, Application and Specification
7.3.2.1 Product A
7.3.2.2 Product B
7.3.3 Cargill Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.3.4 Main Business/Business Overview
7.4 Dowdupont
7.4.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.4.2 Marine Algae Products Product Category, Application and Specification
7.4.2.1 Product A
7.4.2.2 Product B
7.4.3 Dowdupont Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.4.4 Main Business/Business Overview
7.5 Kerry
7.5.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.5.2 Marine Algae Products Product Category, Application and Specification
7.5.2.1 Product A
7.5.2.2 Product B
7.5.3 Kerry Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.5.4 Main Business/Business Overview
7.6 Ingredion
7.6.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.6.2 Marine Algae Products Product Category, Application and Specification
7.6.2.1 Product A
7.6.2.2 Product B
7.6.3 Ingredion Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
7.6.4 Main Business/Business Overview
7.7 CP Kelco
7.7.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
7.7.2 Marine Algae Products Product Category, Application and Specification
7.7.2.1 Product A
7.7.2.2 Product B
7.7.3 CP Kelco Marine Algae Products Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
..…..Continued

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Reliability Leadership Game Launched at The RELIABILITY Conference

Scenario Based Experience Designed to Teach Reliability Leadership

Top quartile or best-practice organizations know that performance is achieved through leadership”

— Terrence O’Hanlon

LAS VEGAS, NEVADA, US, April 26, 2018 /EINPresswire.com/ — Reliabilityweb.com® announces the release of the Reliability Leadership® Game at the 13th Annual RELIABILITY Conference held in Las Vegas, Nevada from April 23-27, 2018.

According to Terrence O'Hanlon, CEO, Reliabilityweb.com, “Most organizations approach reliability as a technical project. Research conducted by Reliabilityweb.com, and confirmed by numerous other sources, shows that this approach fails to generate sustainable business success over 70% of the time.”

Companies in the United States spend $14 billion annually on leadership development. However, according to industry research, the leadership failure rate among senior executives is 50%. Warren Bennis, pioneer of leadership studies, states that it is almost a cliché that a single definition of leadership is lacking.

“Top quartile or best-practice organizations know that performance is achieved through leadership; however, they also realize that results are only delivered through an engaged and empowered workforce,” states O’Hanlon. “Most of the organizations we meet use a small group of reliability specialists to ‘drive’ reliability in the enterprise. They lack a workable plan to engage and empower the entire workforce.”

The Reliability Leadership Game is designed to allow participants to discover for themselves that leadership does not come from one person, it comes from everyone. This is especially true for reliability. It is important to have strong leadership at all levels of the organization, from the front-line workforce, supervisors, managers and executives, in order to create a sustainable, high-performance reliability system.

The Reliability Leadership Game is available in 1-day and 2-day formats. The game will become a regular feature at events like The RELIABILITY Conference (TRC) and the International Maintenance Conference (IMC), both produced by Reliabilityweb.com, as well as other popular industry events. Also available for private, on-site delivery for organizations who wish to train in teams or avoid travel.

For more information, contact: crm@reliabilityweb.com

About Reliabilityweb.com

Created in 1999, Reliabilityweb.com is a community of knowledge and a community of practice focused on advancing reliability and asset management to make stakeholders safer and more successful. The Reliabilityweb.com team works with integrity, authenticity and responsibility. More details are available at www.reliabilityweb.com.

Terrence O'Hanlon CMRP CEO
Reliabilityweb.com
2393332500
email us here


Source: EIN Presswire